chen, chenyan – page 17 – eisai china lnc.-pg电子app

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (rtks) with a novel binding mode, product name: lenvima®/kisplyx®, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: halaven®, “eribulin”) will be presented during the european society for medical oncology (esmo) congress 2016, taking place in copenhagen, denmark, from october 7 – 11.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has been selected for a fourth consecutive year of membership in the dow jones sustainability asia pacific index (djsi asia pacific), the asia pacific version of the dow jones sustainability indices (djsi), which are a family of premier global indices for socially responsible investment (sri).

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it will launch “chocola bb® mouth ulcer repair shot” (third-class otc drug) for mouth ulcers in japan on thursday, august 25. the product is the first oral care spray to be marketed under the chocola bb brand.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its european regional headquarters eisai europe ltd. (location: u.k.) has received a positive opinion from the european medicines agency’s committee for medicinal products for human use (chmp) on anticancer agent lenvatinib mesylate (generic name, “lenvatinib”) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf) targeted therapy. if approved, lenvatinib will be launched under the brand name kisplyx® for this indication.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its pharmaceutical sales subsidiary in mexico, eisai laboratorios, s. de r.l. de c.v. (location: mexico city, “eisai mexico”) has received approval for the antiobesity agent venespri® (lorcaserin hydrochloride, u.s. brand name: belviq®, “lorcaserin”) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (bmi) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related co-morbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) by the federal commission for the protection against sanitary risk (cofepris), the mexico regulatory authority. mexico marks the first country in latin america where lorcaserin is approved. lorcaserin will be marketed in mexico under the brand name venespri.